secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001356576-22-000071
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q3 revenue $177.4M (+19% YoY); guides FY2022 revenue $650-680M
-----------------------------------------------------------------------

- GAAP net earnings $1.7M ($0.03 diluted EPS); adjusted op earnings $25.4M vs $43.3M prior year.
- Total revenues $177.4M (+19% YoY); Qelbree sales $18.3M (+65% QoQ) with 94,328 prescriptions.
- FY 2022 guidance raised: total revenue $650-680M (from $640-680M) and GAAP op earnings $35-45M (from $20-40M).
- FDA issued CRL for SPN-830 (apomorphine device; Parkinson's); no new efficacy/safety trials needed but device and quality info required; Class 2 review timeline (6 months).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/0001356576-22-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/supn-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001356576-22-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer